Ensysce Biosciences vs Rani Therapeutics
ENSC and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSC and RANI compare
Rani Therapeutics is the larger company, worth 9.0 times as much as Ensysce Biosciences ($73.4M against $8.1M).
Rani Therapeutics grew revenue faster over the last twelve months (449% versus 37.9% for Ensysce Biosciences).
Ensysce Biosciences scores higher on the StockData Score (9 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSC | RANI |
|---|---|---|
| Size and price | ||
| Market cap | $8.1M | $73.4M |
| Share price | $0.418 | $0.526 |
| Change, 1 year | −79.7% | −75.2% |
| Change, 5 years | −100.0% | −98.5% |
| Beta (5Y) | 2.59 | 0.85 |
| Employees | 8 | 69 |
| StockData Score | ||
| Total score | 9 (better) | 2 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× (better) | 11.1× |
| P/B | 0.3× (better) | 2.2× |
| FCF yield | – | −31.7% |
| Fair value | $1.73 | $0.366 |
| Margin of safety | 75.8% (better) | −43.8% |
| Growth | ||
| Revenue growth (TTM) | 37.9% | 449% (better) |
| Revenue growth, 5Y average | 5.2% | 28.7% (better) |
| Profitability | ||
| Operating margin | −1477% | −530% (better) |
| Net margin | – | −493% |
| FCF margin | – | −353% |
| Return on equity | – | −249% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −7157.6× | −71.9× (better) |
| Current ratio | 8.02 (better) | 5.26 |
| Altman Z-score | −17.54 | −1.36 (better) |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.7% | 32.7% |
| Held by insiders | 6.2% | 30.6% |
| Insider net buying, 12 months | $444K (better) | $49.7K |
| Short interest, % of float | 0.49% | 8.5% |
Go deeper
- ENSC stock overview
- ENSC income statement
- ENSC valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.